Key facts
- BioFire’s last known valuation is $450.0M (Jan 2014).
- It has raised $1.1M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Draper Associates, 10X Capital, Umami Capital, University of Utah.
- 1 investment vehicle was formed to buy BioFire shares in the last 12 months, reporting $111K sold to 12 investors, per SEC Form D filings.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for BioFire
- ·The full record, as it builds
Funding rounds
No funding rounds for BioFire are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Secondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy BioFire shares, reporting $111K sold to 12 investors. Most recent filing May 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About BioFire
Provider of syndromic infectious disease diagnostic services designed to offer results to patients. The company's services include real-time thermocycling, mutation scanning, and set the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing, and it also has panels to test for viruses, bacteria, and antimicrobial resistance genes, enabling medical businesses to assess the cure of diseases in infants and adults.
- Sector
- Healthcare
- HQ
- Salt Lake City, UT, United States
- Founded
- 1990
- Employees
- 848
- Website
- biofiredx.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
BioFire doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioFire shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioFire in its N-PORT filings yet. We sweep new filings monthly.